The Biologics Market includes a broad range of biological products used to address complex medical conditions. The market is segmented by product type, application, end user, source, and region. Market Research Future reports that the market reached USD 616.25 billion in 2024 and could reach USD 3,338.29 billion by 2035 at a CAGR of 16.6%.

By product type, the market includes monoclonal antibodies, vaccines, cell and gene therapies, recombinant proteins, and hormones. Monoclonal antibodies hold the largest share because of their extensive use in oncology, immunology, and chronic disease management. Cell and gene therapy is developing rapidly because of advances in genetic engineering and personalized medicine.

By application, oncology represents the largest segment, followed by infectious diseases, autoimmune disorders, cardiovascular diseases, and neurological disorders. Hospitals are the leading end users, supported by their specialized infrastructure for biologic treatment administration.

The source segment includes microbial, mammalian, plant, and transgenic animal systems. Mammalian sources currently account for the largest share because they can produce complex proteins with characteristics closely aligned with human biology.

Major companies participating in the market include AbbVie, Amgen, Roche, Johnson & Johnson, Novartis, Bristol-Myers Squibb, Sanofi, Gilead Sciences, and Merck & Co.

Increasing competition, biosimilar development, technological innovation, and strategic investments are expected to shape the future competitive environment.

Gain valuable insights through comprehensive industry analysis:

Spinal Traction Market Trends

Intussusception Market Growth

Measles Market Demand

Acromegaly Market Volume

Primary Ciliary Dyskinesia (PCD) Market Forecast